RG
TEVA icon

Rathbones Group’s Teva Pharmaceuticals TEVA Stock Holding History

Rathbones Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,300
Closed -$91K – 439
2021
Q4 		$91K Hold
11,300
– – ﹤0.01% 410
2021
Q3 		$110K Buy
+11,300
New +$106K ﹤0.01% 406
2016
Q3 		– Sell
-14,056
Closed -$706K – 319
2016
Q2 		$706K Sell
14,056
-220
-2% -$11.7K 0.04% 170
2016
Q1 		$764K Sell
14,276
-1,270
-8% -$74.5K 0.05% 161
2015
Q4 		$983K Sell
15,546
-1,005
-6% -$62.1K 0.06% 138
2015
Q3 		$934K Hold
16,551
– – 0.06% 149
2015
Q2 		$978K Sell
16,551
-1,000
-6% -$61.7K 0.06% 149
2015
Q1 		$1.09M Hold
17,551
– – 0.07% 137
2014
Q4 		$1.01M Buy
17,551
+3,143
+22% +$175K 0.07% 150
2014
Q3 		$774K Hold
14,408
– – 0.05% 163
2014
Q2 		$755K Buy
+14,408
New +$736K 0.05% 164

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Rathbones Group's TEVA Position: Q1 2022 in Review

Rathbones Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 11,300 shares — an estimated $91K sold.

Rathbones Group first reported a position in TEVA in Q2 2014 and held it in 11 quarters. The position peaked at $1.09M in Q1 2015. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Rathbones Group reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Rathbones Group sold 11,300 Teva Pharmaceuticals shares in Q1 2022, an estimated $91K.
  • Rathbones Group first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 11 quarters.
  • Rathbones Group's Teva Pharmaceuticals position peaked at $1.09M in Q1 2015.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Rathbones Group's 13F filing for Q1 2022, filed 11 May 2022.